Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn’s Disease

Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn’s Disease

<b>Background:</b> Ustekinumab (UST) has demonstrated effectiveness in treating patients with Crohn’s disease. Monitoring treatment response can improve disease management and reduce healthcare costs. We investigated whether UST trough levels (TLs), serum IL22, and Oncostatin M (OSM) lev...

Full description

Bibliographic Details
Main Authors: Luisa Bertin, Brigida Barberio, Alessandro Gubbiotti, Lorenzo Bertani, Francesco Costa, Linda Ceccarelli, Pierfrancesco Visaggi, Giorgia Bodini, Andrea Pasta, Renato Sablich, Maria Teresa Urbano, Antonio Ferronato, Andrea Buda, Manuela De Bona, Giulio Del Corso, Alessandro Massano, Imerio Angriman, Marco Scarpa, Fabiana Zingone, Edoardo Vincenzo Savarino
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Journal of Clinical Medicine
Subjects:
inflammatory bowel disease
Crohn’s disease
Oncostatin M
IL-22
ustekinumab trough levels
ustekinumab
Online Access:https://www.mdpi.com/2077-0383/13/6/1539

Internet

https://www.mdpi.com/2077-0383/13/6/1539

Similar Items